APD418

APD418 is a first-in-class, investigational small molecule drug that acts as a selective beta-3 adrenergic receptor antagonist. It was originally developed by Arena Pharmaceuticals and later acquired by Pfizer. The drug is designed to improve cardiac contractility with minimal effect on heart rate and blood pressure, targeting the treatment of acute and decompensated heart failure. Its mechanism involves inhibition of beta-3 adrenergic receptor-mediated myofilament repression in cardiomyocytes, which may enhance cardiac contractile performance without the adverse effects commonly associated with traditional inotropes. Preclinical studies demonstrated positive inotropic (increased force of contraction) and lusitropic (improved relaxation) effects without significant impact on heart rate or systemic blood pressure[2][5][6][10]. Clinical development reached Phase 2 for acute heart failure but was discontinued due to business decisions rather than safety concerns[2][4].

Other names

Vemtoberant